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Immunohistochemical differentiation between
primary adenocarcinomas of the ovary and
ovarian metastases of colonic and breast origin.
Comparison between a statistical and an intuitive
approach
J H Lagendijk, H Mullink, P J van Diest, G A Meijer, C J L M Meijer
Abstract
Aim-To discriminate between adenocar-
cinomas that are primary to the ovary and
metastatic to the ovary, especially of
colonic and breast origin, by immunohis-
tochemistry, using stepwise discriminant
analysis or a decision tree.
Methods-312 routinely processed, forma-
lin fixed tissue specimens were used. The
tumours were divided into a learning set
(n = 159), composed ofprimary tumours of
ovary, breast, and colon, and a test set,
comprising 134 metastases from these sites
and an additional 19 primary ovarian
carcinomas. The immunohistochemical
panel was composed of antibodies against
cytokeratin 7 (CK7) and 20 (CK20), CA125,
vimentin, carcinoembryonic antigen
(CEA), gross cystic disease fluid protein-15
(GCDFP-15), and the oestrogen receptor
(ER). The staining results of the tumours
were expressed as the product of the stain-
ing intensity and the percentage of positive
tumour cells. Analyses were first per-
formed on the learning set and then evalu-
ated on the test set.
Results-Although the immunostaining
patterns showed a considerable overlap
between the three types of adenocarci-
noma, the breast carcinomas were typi-
cally positive for GCDFP-15 and often for
ER, and negative for vimentin. Ovarian
carcinomas were always positive for CK7
and to a lesser extent for CA125. Colonic
carcinomas showed prominent positivity
for CEA and CK20, while no staining was
seen for ER and vimentin. In discriminant
analysis, six antibodies (aCK7, aCK20,
aCA125, aCEA, aER, and aGCDFP-15)
appeared to be necessary for optimal
classification: 89% of the learning set and
82% of the test set were classified cor-
rectly. In the decision tree, only four anti-
bodies (aCK7, aCEA, aER, and aGCDFP-
15) were used to obtain a correct
classification score of89% for the learning
set and 84% for the test set.
Conclusions-Using a semiquantitative
assessment of the immunostaining results
by a restricted panel of six antibodies with
stepwise discriminant analysis, 80-90% of
the adenocarcinomas ofcolon, breast, and
ovary can be correctly classified. Discri-
minant analysis is computer aided and
therefore an easy method and for each
case a probability value of the classifi-
cation result is obtained. The intuitive
decision tree method provides a slightly
better result, requires only four antibod-
ies, and offers a more practical method for
the surgical pathologist.
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Ovarian cancers constitute about 2.3% of all
cancers. In the USA it is the fourth most com-
mon source of cancer death in women,
exceeded only by breast, colorectal, and lung
malignancies.' Cancer of the ovary constitutes
about 25% of the gynaecological cancers. Up
to 7% of the ovarian cancers, however,
comprise metastases from various other
locations.2' About 40% of these originate from
the colon.5-7 These metastases often form large
cystic masses or show abundant necrosis,
mimicking primary endometrioid or mucinous
ovarian carcinoma. They sometimes precede
the diagnosis of the primary tumour. Other
primary tumours that metastasise rather fre-
quently to the ovary are breast carcinomas.
Although the histological pattern is often
suggestive of a metastasis from the breast, the
growth pattern ofthe tumour can mimic that of
a primary carcinoma of the ovary.8 9 Moreover,
the existence of a prior tumour in another
organ may not be known.'"
Because of the different therapeutic ap-
proaches to metastatic carcinomas of ovary,
colorectum, and breast, it is important to
discriminate between metastases of these tu-
mours. Immunohistochemistry can be of great
help in this, but individual antibodies are often
not specific and sensitive enough. Therefore
panels of several antibodies with a higher
combined sensitivity and specificity should be
used.
As a model to study the discriminative
capacity of such a panel for metastatic
tumours, primary tumours were used as a
learning set and metastatic tumours as a test
set. A prerequisite for this is that the immuno-
histochemical profiles ofthe primary adenocar-
cinomas and their metastases are comparable.
Although there were strong indications for this
in published reports," it was checked once
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more for the staining results of our samples
before they were further evaluated.
We used antibodies against cytokeratin 7
(CK7)" '- and cytokeratin 20 (CK20),'5-16
1719 10 2521-7vimentin," CEA,'3'4 CA-125, gross cystic
disease fluid protein 15 (GCDFP-15)," 28 and
the oestrogen receptor (ER),29 32 all of which
have a certain selective reactivity for these
adenocarcinomas.
Staining results were scored semiquantita-
tively as described before,33 and were evaluated
using two different approaches: (1) stepwise
discriminant analysis, and (2) a decision tree.
For both, the staining results were analysed
using the learning set, and the classification
rules obtained were evaluated on the test set.
The stepwise discriminant analysis was carried
out with a suitable computer program, and the
decision tree was constructed intuitively. Based
on the results obtained with each of the two
approaches, antibody panels could be com-
posed whereby the great majority of the
samples could be correctly classified.
Methods
TISSUE
Formalin fixed, paraffin embedded tissue
blocks of human adenocarcinomas of the
breast, colorectum, and ovary, as well as
metastases from these primary tumours (espe-
cially those to the ovary), were randomly
selected from the archives of the departments
of pathology of the General Hospital Gooi-
Noord, Blaricum, Stichting Deventer Zieken-
huizen Deventer, and the Free University Hos-
pital, Amsterdam, The Netherlands. In all
cases the most representative block was se-
lected, as judged on the haematoxylin and
eosin stained sections.
Fifty four primary colorectal, 55 primary
breast, and 50 primary ovarian carcinomas were
used as a learning set. The colorectal tumours
were of various differentiation grades (two well
differentiated, 32 moderately differentiated, 14
poorly differentiated, and six undetermined)
and included different histological types, among
which were a few colloid carcinomas and signet
ring cell carcinomas. The set of breast carcino-
mas comprised 49 ductal carcinomas, five lobu-
lar carcinomas, and one medullary carcinoma.
The group of ovarian carcinomas comprised
serous, mucinous, and endometrioid types of all
differentiation grades (seven well differentiated,
16 moderately differentiated, and 27 poorly dif-
ferentiated).
The test set comprised 134 adenocarcinoma
metastases (46 colonic, 64 breast, and 24 ovar-
ian) and 19 primary ovarian adenocarcinomas
(two well differentiated, six moderately differ-
entiated, and 11 poorly differentiated).
Twenty of the metastases were localised in
the ovary, 12 originating from the breast and
eight from the colorectum. The other metas-
tases, from colorectal and breast primaries,
were mainly derived from locoregional lymph
nodes, liver, bones, and skin (n = 116), and
those from ovarian primaries were predomi-
nantly found in the peritoneum and omentum
(n = 24).
IMMUNOHISTOCHEMISTRY
The antibodies were selected because of their
known reactivity with adenocarcinomas of the
ovary, colorectum, or breast (table 1) and were
suitable for formalin fixed, paraffin embedded
tissue.
Four micron thick sections were cut and
deparaffinised in graded alcohols and xylene.
The sections were then subjected to immuno-
staining, applying a standard avidin-biotin-
peroxidase complex (ABC) method by means
of an automatic staining device (Ventana 320,
Ventana Medical Systems). For CK7, CK20,
and GCDFP-15, the sections were digested
with alkaline protease (proteinase 2, provided
by Ventana), which was done automatically in
the apparatus. Before immunostaining with
CA-125 the sections were digested with 1%
pronase. Before vimentin and ER immuno-
staining, antigen retrieval was carried out by
boiling the sections in citrate buffer (pH 6.0)
for 2 x 10 minutes using a microwave oven.
Only the immunostaining for the ER was done
by hand, using an overnight incubation at 5°C.
In all staining sessions, appropriate positive
and negative control sections were included.
SCORING OF THE IMMUNOSTAINING
The immunostaining was scored semiquantita-
tively by means of a modified histoscore
method,'4 taking into account the staining
intensity and the percentage of positive tumour
cells as described before.3" Briefly, for each
stained section the estimated percentage of
tumour cells was multiplied by the intensity
Table 1 Antibodies usedfor immunostaining of colonic, ovarian, and breast carcinomas and their metastases
Antibody* Dilution Antigen Main specificity Source Reference No
Parlam 1 1:2000 CEA Gastrointestinal tract NKI, Amsterdam, 20, 23
epithelium The Netherlands
Vim 9 1:2000 Vimentin Mesenchymal cells NKI, Amsterdam, 18
he Netherlands
OVTL 12/30 1:80 Cytokeratin 7 Glandular epithelium Sanbio, Uden, 12
except colon The Netherlands
Ks 12.8 1:100 Cytokeratin 20 Colonic epithelium Dako, Glostrup, 16
Denmark
OC-125 1:100 CA-125 Ovarian epithelium ITK, Uithoorn, 25
The Netherlands
BRST-2 1:100 GCDFP-15 Breast epithelium Signet, Dedham, 11, 29
Mississipi, USA
Anti-ER 1:50 ER Nuclei of breast epithelium Dako, Glostrup, 30, 32
Denmark
* All antibodies were mouse monoclonal.
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value (0, 1, 2, or 3). This was taken as the
immunohistochemical score (IS), which could
vary between 0 and 300. An IS value > 10 was
considered positive.
STATISTICAL ANALYSIS
For statistic analysis, the SPSS statistical
program was used. To evaluate the power of the
respective antibodies to discriminate between
the three primary sites, stepwise discriminant
analysis was performed as described
previously."3 In this way, the best combination
of discriminatory antibodies was selected and
classification functions were composed to clas-
sify each case as either colonic, mammary, or
ovarian carcinoma.
The posterior probability values of the
classification of the individual cases were also
obtained. Such values can be useful in daily
practice as an indication of the certainty of the
classification result. We introduced the condi-
tion that the posterior probability value had to
be more than 0.8; this means that the certainty
of a classification result is more than 80%. We
feel that in daily practice this is about the mini-
mum acceptable certainty.
DECISION TREE APPROACH
In order to get a more practical approach for
the surgical pathologists to discriminate be-
tween the different adenocarcinomas, a flow
chart was developed, also based on the IS
values of the learning group specimens. This
approach was carried out intuitively, using as
few steps and as few antibodies as possible.
Results
STAINING RESULTS OF THE LEARNING SET
Table 2 shows the mean IS values for the
different antigens obtained in the learning and
test sets of the colorectal, ovarian, and breast
carcinomas. In table 3 the percentage of
samples positive (IS > 10) for the different
markers is shown.
In ovarian carcinomas, cytoplasmic staining
was generally seen with antibodies against CK7
and, when present, also with a-vimentin. Most
tumours showed expression of CA125 at the
cell membrane, usually at the luminal site but
occasionally also in the cytoplasm. Only in
mucinous ovarian carcinomas was a cytoplas-
mic staining for CK20 and a membranous
staining for CEA sometimes seen. One third of
the tumours of the ovary showed some
(nuclear) positivity for ER. From the ovarian
carcinomas, the mucinous subtype had a
slightly different staining pattern: the mean
ISCEA and IS,K0 values in this subtype were 66
and 75, while the mean IS values for these
antibodies in the total set of ovarian carcino-
mas were only 30 and 27, respectively. The
mucinous tumours were also less intensely
stained for CA125 (mean IS, 36) than all ovar-
ian carcinomas as a group (mean IS, 64).
Most colorectal carcinomas showed an
abundant strong cytoplasmic staining for CEA
and to a lesser extent for CK20, while CEA
often showed strong membrane staining as
well. Occasionally a certain degree of cytoplas-
mic staining for CK7 was seen, but the
intensity was rather weak and the number of
positive tumour cells was limited. CA125
showed only weak membranous staining in a
few samples. Most colorectal carcinomas were
positive for CEA and CK20. In signet ring cell
carcinomas the IS for CK20 was very low: the
mean IS value was 3, compared with 138 for
the total group of colorectal carcinomas. In the
colloid subtype the IS,K0 varied considerably
as compared with the mean IS of all colorectal
carcinomas. Other significant differences in the
IS in subtypes of the colorectal carcinomas
were not found.
Table 2 Immunoscore (IS) for each antibody in the learning and test sets
n GCDFP-15 CEA ER CK20 CK7 CA125 Vimentin
Learning set
Colorectal carcinoma 48 0 (1) 185 (73) 0 (0) 138 (87) 22 (53) 6 (16) 1 (2)
Breast carcinoma 43 69 (61) 26 (45) 56 (81) 16 (35) 211 (93) 11 (27) 5 (15)
Ovarian carcinoma 43 1 (4) 30 (59) 7 (19) 27 (59) 161 (97) 64 (66) 40 (66)
Test set
Metastatic colorectal carcinoma 46 0 (2) 190 (79) 0 (0) 153 (94) 37 (88) 6 (15) 3 (18)
Metastatic breast carcinoma 64 70 (73) 40 (77) 43 (65) 11 (32) 197 (111) 11 (35) 7 (25)
Metastatic ovarian carcinoma 24 0 (1) 29 (47) 15 (30) 42 (63) 225 (73) 87 (91) 32 (63)
Primary ovarian carcinoma 19 1 (3) 20 (44) 4 (14) 29 (57) 174 (96) 63 (66) 35 (63)
Values are mean (SD).
Table 3 Positive samples (immunostaining score> 10) for each antibody in learning and test sets
n GCDFP-15 CEA ER CK20 CK7 CA125 Vimentin
Learning set
Colorectal carcinoma 48 0 (0) 47 (98) 0 (0) 42 (87.5) 11(23) 6 (12.5) 0 (0)
Breast carcinoma 43 33 (77) 17 (40) 25 (58) 8 (19) 40 (93) 10 (23) 4 (9)
Ovarian carcinoma 43 0 (0) 12 (28) 5 (12) 16 (37) 39 (91) 27 (63) 16 (37)
Test set
Metastatic colorectal carcinoma 46 0 (0) 46 (100) 0 (0) 40 (87) 8 (17) 7 (15) 2 (4)
Metastatic breast carcinoma 64 47 (73) 26 (41) 27 (42) 11 (17) 54 (84) 11 (17) 5 (8)
Metastatic ovarian carcinoma 24 0 (0) 9 (38) 5 (21) 12 (50) 23 (96) 18 (75) 7 (29)
Primary ovarian carcinoma 19 0 (0) 4 (21) 1 (5) 10 (53) 19 (100) 15 (79) 6 (32)
Values are n (%).
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Table 4 Classification rules obtainedfor the primary sites of colorectal, breast, and ovarian carcinomas
Colorectal carcinomas -0.010 * (IS)GCDFP-15 + 0.046 * (IS)CEA- 0.008 * (IS)ER + 0.021 * (IS)K20 + 0.019 *
(IS)K7 + 0.124 * (IS)CA-125 - 6.907
Breast carcinomas 0.350 * (IS)GCDFP-15 + 0.016 * (IS)CEA + 0.024 * (IS)ER + 0.001 * (IS)K20 + 0.031 *
(IS)K7 - 0.013 * (IS)CA-125 - 6.175
Ovarian carcinomas -0.127 * (IS)GCDFP-15 + 0.008 * (IS)CEA + 0.003 * (IS)ER + 0.006 (IS)K20 + 0.021 *
(IS)K7 + 0.031 (IS)CA-125 - 3.998
Breast carcinomas usually showed cytoplas-
mic staining for CK7 and GCDFP-15 and
nuclear ER staining. aGCDFP-15 showed an
exclusive positivity in breast carcinomas, and
also ISER > 95 could only be found in these
tumours. In a few cases some cytoplasmic
staining for vimentin and CK20 was seen, as
well as combined membranous and cytoplas-
mic positivity for CEA. Some cases showed
weak CA125 membranous staining. No differ-
ences were found in immunostaining between
subtypes of breast carcinomas.
TEST SET
Comparison of the immunohistochemical pro-
files of primary tumours (ISPn,,) and metastases
(ISme.) showed only a few minor differences for
colorectal and breast carcinomas (table 2). In
some ovarian carcinomas slight variations be-
tween primary tumours and metastases were
observed, but these were not statistically signifi-
cant. The mean (SD) ISER was more than
doubled in the metastases (ISPi,, 7 (19) and 4
(14) in the learning and test sets, respectively;
ISmetaO 15 (30)), with a greater variation. The
metastases of ovarian carcinomas also showed a
higher mean ISCK7 (ISmeta, 225 (73); ISprim3 161
(97)). Other antibodies did not show clear
differences between the primaries and the
metastases.
STEPWISE DISCRIMINANT ANALYSIS
In the learning set, the antibodies against CEA,
GCDFP-15, CA125, CK7, ER, and CK20
were selected in this order by stepwise
discriminant analysis. The obtained classifi-
cation rules for each primary localisation are
given in table 4. In this way the individual sam-
ples were classified (according to the highest
score from either formula) and for each classi-
fication the posterior probability was obtained.
For the learning set a correct classification of
98% (53/54) of the colorectal carcinomas, 88%
(44/50) of the tumours of the ovary, and 80%
(44/55) of the breast carcinomas was obtained.
The overall percentage correctly classified
Table 5 Classification results considering only classification with a posterior probability
(PP) > 0.8 ("certain")
Classified as PP >0. 8 (%a)
Number with
n PP >0.8 (0/6) Colonic Breast Ovarian
Learning set
Colorectal carcinoma 54 50 (93) 49 (98) 0 1 (2)
Breast carcinoma 55 40 (73) 0 38 (95) 2 (5)
Ovarian carcinoma 50 32 (64) 2 (6) 0 30 (94)
Test set
Metastatic colorectal carcinoma 47 38 (81) 38 (100) 0 0
Metastatic breast carcinoma 65 47 (72) 2 (4) 39 (83) 6 (13)
Metastatic ovarian carcinoma 24 17 (71) 0 0 17 (100)
Primary ovarian carcinoma 19 15 (79) 0 0 15 (100)
tumours was 89%. The classification results
were about equally good for the different
differentiation grades (data not shown), so
poorly differentiated cancers were also usually
correctly classified. Classification results were
also nearly equally good for the different
subtypes of breast cancer (data not shown).
When applying the classification formulas
obtained to the test set, 91% (42/46) of the
colorectal metastases, 79% (19/24) of the ovar-
ian metastases, and 74% (47/64) of the breast
metastases were correctly classified. Of the 20
metastases to the ovary, 65% were correctly
classified. Ninety per cent of primary tumours
of the ovary were correctly classified in the test
set (17/19). The overall correct classification of
the test set samples (metastases and primaries)
was 82%.
When considering only the "certain" classifi-
cations with a posterior probability value of 0.8
or more, 122 tumours of the learning set (77%
of the total) could be classified. Of these, 98%
of the carcinomas of the colorectum, 95% of
the breast, and 94% of the ovary were correct
(table 5). Of the 122 tumours with a posterior
probability value of 0.8 or more, the overall
correct classification was 96%; one colorectal,
two breast, and two ovarian carcinomas were
classified falsely as originating from the ovary,
the ovary, and the colorectum, respectively.
The results correspond to correct identification
in 91% of the colorectal carcinomas, 69% of
the breast carcinomas, and 60% of the ovarian
carcinomas from the original learning group
(n = 159). In this setting, the differentiation
grade had no impact on the classification
results.
Using the posterior probability of > 0.8 as
the threshold value for the test set, 77%
(117/153) were classified as "certain" -100%
(38/38) of the colorectal carcinomas, 83% (39/
47) of the breast carcinomas, and 100%
(32/32) of the carcinomas of the ovary. Two of
the falsely classified metastases of the breast
were misclassified as originating from the
colon, while the other six were classified falsely
as carcinomas of the ovary. The overall correct
classification of the 117 tumours of the test set
was 93% (table 5). These results correspond to
a correct identification of 81% of the adenocar-
cinomas of the colon, 60% of the breast, and
67% of the ovary from the original test set.
DECISION TREE ANALYSIS
A decision tree was developed intuitively, based
on the IS values of the learning set samples and
the number of correctly classified samples, in
such a way that the number of correctly classi-
fied samples was as high as possible in each
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Figure 1 Decision tree for the differential diagnosis of adenocarcinomas of colorectum,
breast, and ovary. IScEA, immunoscore for carcinoembryonic antigen; IScK7, immunoscore
for cytokeratin 7 antigen; ISER, immunoscore for oestrogen receptor; SGCDFP, immunoscore
for gross cystic disease fluid protein-15.
step. The flow chart constructed was eventually
composed of only three discriminating steps
(fig 1).
In the first two steps, tumours were classified
as of breast origin when the IS score for
GCDFP-15 was > 10 (step 1) or the IS score
for ER was > 95 (step 2). In these two steps 44
of 55 breast carcinomas of the learning set
could be classified correctly. In the third step,
tumours with an ISCEA/ISCK7 ratio more than 1
were classified as colorectal carcinomas. Here
all colorectal carcinomas of the learning group
were correctly classified (54/54), while seven
adenocarcinomas of the ovary (43/50) and one
carcinoma of the breast (1/10) were misclassi-
fied as of colorectal origin.
The remaining group of tumours, which
were classified as ovarian carcinoma, consisted
of 43 carcinomas of the ovary and 10 misclas-
sified breast carcinomas. In this way, an overall
correct classification of the learning set of 89%
was obtained. No relation was seen between
the differentiation grade or breast cancer
subtype and the classification results.
Table 6 Results of decision tree analysis of learning and test sets
Step 1 Step 2 Step 3 Rest
Classified as: Correctly
classified
n Breast Breast Colonic Ovarian (%o)
Learning set
Colorectal carcinoma 54 0 0 54 0 100
Breast carcinoma 55 42 2 1 10 80
Ovarian carcinoma 50 0 0 7 43 86
Test set
Metastatic colorectal carcinoma 46 0 0 41 5 89
Metastatic breast carcinoma 64 46 3 3 12 72
Metastatic ovarian carcinoma 24 0 0 1 23 96
Primary ovarian carcinoma 16 0 0 1 18 95
When testing this flow chart on the test set
samples, in the first two steps no misclassifica-
tions of ovarian or colonic carcinomas oc-
curred and also 49 of 64 metastases of the
breast carcinomas were classified correctly,
corresponding to 77% correct classification. In
the third step, 41 of 46 metastases of adenocar-
cinomas of colonic origin could be correctly
classified, while there were four falsely classi-
fied metastases (one of ovarian and three of
breast origin). The remaining group, classified
as ovarian, included 23 metastases of ovarian,
12 ofbreast, and five of colorectal origin. Ofthe
20 metastases to the ovary, 90% were correctly
classified as of either colonic or breast origin.
The overall correct classification of the metas-
tases was 82% (table 6). Of the 19 primary
adenocarcinomas of the ovary in the test set, 18
were correctly classified. In all, 84% of the test
group samples were correctly classified.
Discussion
Metastatic adenocarcinomas to the ovary are a
diagnostically important group of ovarian
neoplasms2 because they often are misinter-
preted as primary tumours. One of the reasons
is that the metastases originate from an
unknown primary site. The largest group of
metastases to the ovary are derived from
primaries within the gastrointestinal tract
(47%), of which the great majority was
reported as colorectal,4 while metastases from
the breast are the second largest group.
Gagnon and Tetu9 described 165 ovarian
metastases of which 59 (38%) originated from
the breast.
Recognition of metastases to the ovary also
depends on the knowledge of the frequency
with which certain primary tumours metasta-
sise to this site, the clinical history, a thorough
examination of the patient, and the evaluation
of macroscopic and microscopic characteris-
tics,'° extended by specialised techniques such
as immunohistochemistry.
The present study was performed to make an
objective interpretation of immunohistochemi-
cal data in the differential diagnosis of
metastases from colorectal and breast adeno-
carcinomas, and of metastatic or primary ovar-
ian carcinomas. For this purpose we selected
antibodies with certain well known specificities
for various primary and metastatic tumours at
the three sites. We started with the assumption
that the immunohistochemical profiles of
primary adenocarcinomas of colon, ovary, and
breast are comparable with those of their
metastases. Although there were some indica-
tions of this in published reports,"1 we checked
the hypothesis further. The primary adenocar-
cinomas of colon and breast and their metas-
tases showed no significant differences in
expression. Only in ovarian carcinomas were
some minor differences found between the IS
values-the metastases had a higher IS for
CK7 and ER. Because this difference did not
seem important, the study was performed as
planned. The results show that no real
differences were found between the percent-
ages of correctly classified ovarian metastases
and primaries compared with the other adeno-
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carcinomas (table 5).Therefore, our model was
considered to be valid. The primary adenocar-
cinomas were used as a learning set to define
the antigen profiles, and they were subse-
quently used to discriminate the test set of
metastatic tumours supplemented by a limited
number of primary ovarian adenocarcinomas.
This supplement of 19 primary ovarian carci-
nomas was added to compare this group of
tumours with the 20 ovarian metastases of
colon and of breast origin. Immunostaining
was scored semiquantitatively, taking into
account staining intensity and the percentage
of stained cells. This scoring system has proved
to be reproducible" and has the advantage that
tumours can be discriminated in spite of less
obvious staining differences.
Two approaches were used to analyse the
results of the immunostaining. The first
method was a stepwise discriminant analysis, in
which antibodies against CEA, GCDFP-1 5,
CA125, CK7, CK20, and ER were needed for
an optimum result. The best classification
results were obtained for colorectal carcinomas
and the worst for breast carcinomas, although
for the latter the two most specific tumour
markers are used, namely GCDFP-15 and ER
(see tables 2 and 3). The reason for this seem-
ing contradiction is because in stepwise discri-
minant analysis the combined sensitivity and
specificity of all the antibodies determines the
sequence of the antibodies to be entered in the
analysis. In contrast, in the decision tree proce-
dure, the sequence of the steps is determined
by the specificity of the antibodies only.
Stepwise discriminant analysis and decision
tree analyses showed nearly the same results. In
both cases, the learning sets even showed
exactly the same overall result. There were only
some small differences when the results were
compared for the different tumour groups. In
the test set, the results of the decision tree
analysis were slightly better: two more breast
carcinomas and four more carcinomas of the
ovary were classified correctly, with the use of
fewer antibodies. The total proportion of
correctly classified tumours in the test set was
82% for the stepwise discriminant analysis and
86% for the decision tree analysis. In addition,
with the decision tree, more of the metastases
to the ovary were correctly classified (90%)
than with the stepwise discriminant analysis
(65%). These results, together with the sim-
plicity of the method, support the use of the
decision tree approach.
Histological subtype or differentiation grade
did not influence the classification results for
the different cancers. This indicates that
expression of the relevant antigens is retained
in different histological subtypes and with
increasingly poor differentiation grade, and
also after dissemination. The proposed system
is therefore considered to be robust, and useful
in clinical practice where most problems are
encountered with the most poorly differenti-
ated cancers.
In the stepwise discriminant analysis, CEA
turned out to be the tumour marker with the
highest discriminative value. This was also
found previously for the differential diagnosis
of only ovarian v colorectal carcinoma.33
Although its usefulness is doubtful for the dis-
crimination of mucinous ovarian carcinomas,
which, like colorectal carcinomas, often express
CEA strongly,6 7 22 we were able to classify 13 of
19 primary and eight of nine metastatic muci-
nous ovarian carcinomas correctly in the deci-
sion tree approach.
The effectiveness ofaCEA in this differential
diagnosis is due at least in part to the
semiquantitative evaluation of the sections,
which allows the evaluation of small differences
in staining (table 2).
The discriminative power of GCDFP- 1 5 in
this analysis was evident; between 70% and
80% of the primary or metastatic breast carci-
nomas could be classified, while there were no
false positives. Although aGCDFP- 1 5 is
known to be positive not only in breast
carcinomas but also in carcinomas of the
salivary glands, sweat glands, and prostate and
in some non-neoplastic tissue,28 this does not
play a role in the present differential diagnosis.
The percentage of positive primary and
metastatic breast carcinomas was in accord-
ance with the results of Wick et al." The
CA125 antibody was the third one included in
the stepwise discriminant analysis. It was
reported to be relatively effective in differenti-
ating Mullerian tissue derived adenocarcino-
mas from other types of adenocarcinoma.27 In
the stepwise discriminant analysis, we were
able to confirm this. As described by Loy et al,26
CA125 was expressed in about 60% of the
ovarian adenocarcinomas, while in colonic car-
cinomas only 4% and in breast carcinomas
13% of the tumour cells were stained. In our
study, seven of 63 primary colorectal carcino-
mas (11%) were positive and 42 of 63 (67%)
showed no labelling at all, while in ovarian
adenocarcinomas 47 of 69 (68%) were posi-
tive. Here, only 12 of 69 of the primary
carcinomas (17%) were completely negative.
The number of positive breast carcinomas fell
in between (20%). The differences were
sufficient for CA125 to play a role in the step-
wise discriminant analysis. In contrast, CA125
was not used in the decision tree procedure.
Further analysis of the decision tree rest group
("ovarian carcinomas") with CAl 25 (IS > 80)
resulted in only one additional correctly classi-
fied carcinoma of the ovary.
CK7 was only included in the stepwise
discriminant analysis at step 4. It separates the
colorectal carcinomas from the other tumours.
The primary mucinous ovarian tumours could
also be differentiated very well from colonic
carcinomas, owing to large differences in the
mean IS (table 2).33 Our results, however, were
not as absolute as those described by Ber-
ezowski et al" and others,'2 14 who found that
ovarian tumours, including the mucinous type,
are consistently positive for CK7 whereas
colonic carcinomas are consistently negative.
ER was only included in the stepwise discri-
minant analysis at step 5. The reason for this is
probably the low mean IS value and its overlap
with GCDFP-1 5 (table 2). In contrast to the
reports by Takeda et al 3 and Ollayos,32 all our
colorectal carcinomas were negative. In the
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decision tree procedure, the use of the ER anti-
body added two and three additional correctly
classified cases to the learning set and test set,
respectively. No ovarian carcinomas were
falsely added to the group of breast carcinomas
because of the IS threshold value of 95.
In recent reports,2 16 CK20 was proposed as
a important tool to differentiate between
adenocarcinomas of colonic and ovarian origin
because of its exclusive presence in colorectal
carcinomas and only occasional positivity in
mucinous ovarian carcinomas. As already
described, CEA has much higher discrimina-
tory power than CK20,33 which is also
illustrated by the mean IS values (table 2).
CK20 was only included in the stepwise discri-
minant analysis in the last step and was not
used in the decision tree procedure.
Vimentin did not contribute to the classifi-
cation results in the stepwise discriminant
analysis, although it was found in some ovarian
carcinomas."7-19 The mean IS value of ovarian
carcinomas was probably too low to play a
discriminating role in the stepwise discriminant
analysis. It was also not used in the decision tree.
The results in this study are reasonably com-
parable for both analyses and lie in between
80% and 90% correctly classified cases. A dif-
ference between the stepwise discriminant
analysis and the decision tree analysis is the
number of antibodies to be used. Although this
may vary a little because of variations in the
particular antibodies and laboratory practice,
in our study it turned out that six antibodies
(aCEA, aGCDFP-15, aCA125, aCK7, aER,
and caCK20) are needed in the stepwise discri-
minant analysis, and only four of them
(aGCDFP-15, aER, aCEA, and aCK7) are
needed in the decision tree. Therefore the
decision tree method has the advantage that it
is cheaper and, moreover, it can be performed
immediately when evaluating the sections. It
therefore seems to be a more practical method
for the surgical pathologist. On the other hand,
stepwise discriminant analysis provides a com-
puter aided, statistics based method for the
classification of the adenocarcinomas. With
this method, probability values for a correct
diagnosis are generated. Moreover, the results
obtained can easy be stored in a computer and
verified by clinical follow up, and the antibody
performance can be evaluated periodically.
Newly developed and clinically verified anti-
bodies can be added to modify the classifi-
cation rule. Also the clinically verified cases can
be added to the learning set to enhance the
reliability of the stepwise discriminant analysis.
Summarising, the -method of scoring
immunostaining semiquantitatively and ana-
lysing the results by either a stepwise discrimi-
nant analysis or a decision tree offers the possi-
bility of differentiating primary ovarian
carcinomas from metastatic colorectal and
breast adenocarcinomas to the ovary. With
both approaches it is possible to classify
85-90% of cases correctly.
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